International Assets Investment Management LLC Acquires 38,780 Shares of MannKind Co. (NASDAQ:MNKD)

International Assets Investment Management LLC grew its holdings in shares of MannKind Co. (NASDAQ:MNKD) by 277.0% in the fourth quarter, HoldingsChannel.com reports. The fund owned 52,780 shares of the biopharmaceutical company’s stock after purchasing an additional 38,780 shares during the period. International Assets Investment Management LLC’s holdings in MannKind were worth $192,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of MNKD. SG Americas Securities LLC bought a new stake in shares of MannKind during the 3rd quarter valued at about $293,000. Private Trust Co. NA bought a new stake in shares of MannKind during the 3rd quarter valued at about $41,000. Commonwealth Equity Services LLC boosted its position in shares of MannKind by 7.6% during the 3rd quarter. Commonwealth Equity Services LLC now owns 95,432 shares of the biopharmaceutical company’s stock valued at $394,000 after acquiring an additional 6,760 shares during the last quarter. Raymond James & Associates boosted its position in shares of MannKind by 19.2% during the 3rd quarter. Raymond James & Associates now owns 335,826 shares of the biopharmaceutical company’s stock valued at $1,387,000 after acquiring an additional 54,046 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of MannKind by 32.0% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 61,590 shares of the biopharmaceutical company’s stock valued at $254,000 after acquiring an additional 14,941 shares during the last quarter. Institutional investors own 49.55% of the company’s stock.

MannKind Price Performance

NASDAQ:MNKD opened at $4.23 on Monday. The business has a 50 day moving average of $4.35 and a 200 day moving average of $3.91. The company has a market capitalization of $1.14 billion, a price-to-earnings ratio of -84.60 and a beta of 1.28. MannKind Co. has a 1-year low of $3.17 and a 1-year high of $5.75.

MannKind (NASDAQ:MNKD) last announced its quarterly earnings results on Tuesday, February 27th. The biopharmaceutical company reported $0.01 EPS for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.02. The company had revenue of $58.47 million during the quarter, compared to analysts’ expectations of $52.36 million. As a group, sell-side analysts anticipate that MannKind Co. will post 0.1 EPS for the current year.

Analyst Ratings Changes

A number of research firms recently weighed in on MNKD. Wedbush restated an “outperform” rating and issued a $10.00 target price on shares of MannKind in a research report on Wednesday, February 28th. Cantor Fitzgerald restated an “overweight” rating and issued a $6.50 target price on shares of MannKind in a research report on Friday, March 15th. Finally, HC Wainwright restated a “buy” rating and issued a $7.50 target price on shares of MannKind in a research report on Thursday, January 4th.

MannKind Profile

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.